内容紹介
Two Cases of Recurrent GIST Successfully Treated with Imatinib Mesylate at 100 mg/day
Summary
Case 1: Recurrent tumors from gastric GIST in the liver and the abdominal wall showed partial response with 200 mg/day imatinib and maintained partial response at 100 mg/day. Case 2: Metastatic liver tumors from the jejunal GIST showed partial response with 200 mg/day imatinib. The tumors have been enlarged for interruption of imatinib administration, however, re-treatment with imatinib resulted in partial response again and kept partial response at 100 mg/day of imatinib. The two cases seldom encountered adverse events at 100 mg/day of imatinib. There are some cases successfully treated with low-dose imatinib mesylate for recurrent GIST.
要旨
症例1は,胃GISTの肝・腹壁転移に対しイマチニブ200 mg/日でPRが得られ,100 mg/日でPRを維持している。症例2は,空腸GISTの肝転移に対しイマチニブ200 mg/日でPRが得られたが治療中断で再増大し,イマチニブ200 mg/日投与で再びPRが得られ,100 mg/日でPRを維持している。2症例とも副作用はほとんど認めない。再発GISTに対するイマチニブ投与は,低用量で効果が期待できる症例も少なくない。
目次
Summary
Case 1: Recurrent tumors from gastric GIST in the liver and the abdominal wall showed partial response with 200 mg/day imatinib and maintained partial response at 100 mg/day. Case 2: Metastatic liver tumors from the jejunal GIST showed partial response with 200 mg/day imatinib. The tumors have been enlarged for interruption of imatinib administration, however, re-treatment with imatinib resulted in partial response again and kept partial response at 100 mg/day of imatinib. The two cases seldom encountered adverse events at 100 mg/day of imatinib. There are some cases successfully treated with low-dose imatinib mesylate for recurrent GIST.
要旨
症例1は,胃GISTの肝・腹壁転移に対しイマチニブ200 mg/日でPRが得られ,100 mg/日でPRを維持している。症例2は,空腸GISTの肝転移に対しイマチニブ200 mg/日でPRが得られたが治療中断で再増大し,イマチニブ200 mg/日投与で再びPRが得られ,100 mg/日でPRを維持している。2症例とも副作用はほとんど認めない。再発GISTに対するイマチニブ投与は,低用量で効果が期待できる症例も少なくない。